Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | PO / MO |
The patient took first dose correctly, and 24 hours late took second dose of Vivotif; The patient took third dose of Vivotif with food; Case reference number US-BN-2025-001142 is a spontaneous case initially received from a pharmacist via Communication (reference number: USBAV25-1593) on 01-Jul-2025 and concerns a 57-years-old male patient. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient took first dose of Vivotif correctly (batch number: unknown), at an unknown dose, orally for indication typhoid immunization. On an unspecified date, 24 hours late, the patient took second dose of Vivotif (batch number: unknown), at an unknown dose, orally (explicitly coded as 'inappropriate schedule of product administered'). On an unspecified date, unknown amount of time after first dose, the patient took third dose of Vivotif with food (batch number: unknown), at an unknown dose, orally (explicitly coded as 'product administration error'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif. No further information was provided.; Reporter's Comments: A 57-year-old male patient took the second dose of Vivotif reported as 24 hours late, which is considered as inappropriate schedule of product administered. The patient took the third dose of Vivotif with food, which is considered as product administration error. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of product administration and product administration error are considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration and product administration error are not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 57-year-old male patient took the second dose of Vivotif reported as 24 hours late, which is considered as inappropriate schedule of product administered. The patient took the third dose of Vivotif with food, which is considered as product administration error. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of product administration and product administration error are considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration and product administration error are not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.